ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We use a double transgenic model of CML, where BCR-ABL expression is induced in stem cells [21], and demonstrate that Lys05 treatment consistently inhibits autophagy in CML LSCs in vivo, while HCQ approximating clinically achievable concentrations fails to do so.